DNA vaccines for cancer therapy

Bibliography

• IOANNIDES CG, PLATSOUCAS CD, O'BRIAN CA et al: Viral oncolysates in cancer treatment: Immunological mechanisms of action (review). AntiCancer Res. (1989) 9:535–544.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO: Experimental and clinical studies with active specific immunotherapy. Prog. Clin. Biol. Res. (1989) 288:309–321.
   PubMedGoogle Scholar
• MINEV BR, MCFARLAND BJ, SPIESS PJ et al.: Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. (1994) 54:4155–4161.
   PubMedGoogle Scholar
• NOGUCHI Y, RICHARDS EC, CHEN YT, OLD U. Influenceof interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA(1995) 92(6):2219–2223.
   PubMed Web of Science ®Google Scholar
• OVERWIJK WW, LEE DS, SURMAN DR et al: Vaccination with a recombinant vaccinia virus encoding a 'self antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lympho-cytes. Proc. Natl. Acad. Sci. USA (1999) 96:2982–2987.
   PubMed Web of Science ®Google Scholar
• HIRSCHOWITZ EA, LEONARD S, SONG W et al.: Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. (1998) 5:975–983.
   PubMed Web of Science ®Google Scholar
• TAKASHIMA A, MORITA A: Dendritic cells in geneticimmunization. j Leukoc. Biol. (1999) 66(2)350–356.
   Google Scholar
• TARTE K, KLEIN B: Dendritic cell-based vaccine: apromising approach for cancer immunotherapy. Leukemia (1999) 13(5):653–663.
   PubMed Web of Science ®Google Scholar
• AVIGAN D: Dendritic cells: development, function andpotential use for cancer immunotherapy. Blood Rev. (1999) 13(1):51–64.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, YU Q, PIRAINO ST et al.: Induction ofantitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. (1999) 163:699–707.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ etal.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for treatment of patients with metastatic melanoma. Nature Med. (1998) 4 (3):321–327.
   Google Scholar
• •Human clinical trial of peptide-based delivery of an immunodominant epitope of the melanoma tumour antigen, gp100.
   Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. (1998) 4(3):328–332.
   PubMed Web of Science ®Google Scholar
• •Human clinical trial of a dendritic cell vaccine in melanoma patients.
   Google Scholar
• WOLFF JA, MALONE RW, WILLIAMS P et al.: Direct genetransfer into mouse muscle in vivo. Science (1990) 247:1465–1468.
   PubMed Web of Science ®Google Scholar
• LAI WC, BENNETT M: DNA vaccines. Grit. Rev. Immunol. (1998) 18:449–484.
   PubMed Web of Science ®Google Scholar
• ••Detailed review of preclinical studies of DNA vaccines forinfectious disease.
   Google Scholar
• DONNELLY JJ, ULMER JB, SHIVER JW, LIU M: DNA vaccines. Ann. Rev. Immunol. (1997) 15:617–648.
   PubMed Web of Science ®Google Scholar
• ••Review of immune responses to DNA vaccines and safetyconsiderations.
   Google Scholar
• WANG R, DOOLAN DL, LE TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476–480.
   PubMed Web of Science ®Google Scholar
• ••First trial of a pDNA vaccine in healthy human volunteers.
   Google Scholar
• BOON T, CEROTTINI J-C, VAN DEN EYNDE B, VAN DERBRUGGEN P, VAN PEL A: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: A new era for cancer immunotherapybased on the genes that encode cancer antigens. Immunity (1999) 10:281–287.
   PubMed Web of Science ®Google Scholar
• •Description of tumour antigen genes and discussion of cancer vaccine strategies.
   Google Scholar
• ROSENBERG SA: Cancer vaccines based on the identifi- cation of genes encoding cancer regression antigens. Immunol. Today (1997) 18:175–182.
   PubMedGoogle Scholar
• ••Review of early work on identification of melanoma tumourantigens.
   Google Scholar
• BAKKER ABH, SCHREURS MWJ, DE BOER AJ et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. (1994) 179:1005–1009.
   Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Identifi-cation of a melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA (1994) 91:6458–6462.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. ScL USA (1994) 91:3515–3519.
   PubMed Web of Science ®Google Scholar
• BRICHARD V, VAN PEL A, WOLFEL T et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. (1993) 178:489–495.
   PubMed Web of Science ®Google Scholar
• WANG RF, ROBBINS PF, KAWAKAMI Y, KANG X-Q, ROSENBERG SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. (1995) 181:799–804.
   PubMed Web of Science ®Google Scholar
• WANG R-F, APPELLA E, KAWAKAMI Y, KANG X, ROSENBERG SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. (1996) 184:2207–2216.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643–1647.
   Google Scholar
• BOEL P, WILDMANN C, SENSI ML eta].: RAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 2(2):167–175.
   Google Scholar
• VAN DEN EYNDE B, PEETERS 0, DE BACKER 0 et al: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. (1995) 182(3):689–698.
   PubMed Web of Science ®Google Scholar
• NEUMANN E, ENGELSBERG A, DECKER J et al.: Heteroge-neous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immuno-therapies? Cancer Res. (1998) 58(18)4090–4095.
   Google Scholar
• CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. ScL USA (1997) 94(5):1914–1918.
   PubMed Web of Science ®Google Scholar
• COUSSENS L, YANG-FENG TL, LIAO YC et al.: Tyrosinase kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 230(4730):1132–1139.
   PubMed Web of Science ®Google Scholar
• THOMPSON JA, GRUNERT F, ZIMMERMAN W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. (1991) 5(5):344–366.
   PubMed Web of Science ®Google Scholar
• ABRAMS SI, HAND PH, TSANG KY, SCHLOM J: Mutant rasepitopes as targets for cancer vaccines. Semin. Oncol (1996) 23(0:118–134.
   PubMedGoogle Scholar
• WEIJZEN S, VELDERS MP, KAST WM.: Modulation of theimmune response and tumor growth by activated Ras. Leukemia (1999) 13(4):502–513.
   Google Scholar
• THEOBOLD M, BIGGS J, DITTMER D, LEVINE AJ,SHERMAN LA: Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA (1995) 92(26):11993–11997.
   PubMedGoogle Scholar
• MAYORDOMO JI, LOFTUS DJ, SAKAMOTO H et al.: Therapy of murine tumors with p53 wild-type and mutant sequence peptide vaccines. J. Exp. Med. (1996) 183(4)1357–1365.
   Google Scholar
• BIANCHI A, MASSAIA M: Idiotypic vaccination in B-cellmalignancies. Mol. Med. Today (1997) 3(10435–441.
   Google Scholar
• KWAK LW, THIELEMANS K, MASSAIA M: Idiotypic vaccination as therapy for multiple myeloma. Semin. Hematol. (1999) 36(1 Suppl. 3):34–37.
   Google Scholar
• SPOONER RA, DEONARAIN MP, EPENETOS AA: DNA vaccination for cancer treatment. Gene Ther. (1995) 2:173–180.
   PubMed Web of Science ®Google Scholar
• WANG B, MERVA M, DANG K et al. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum. Gene Ther. (1995) 6(4):407–418.
   PubMed Web of Science ®Google Scholar
• CONRY RM, LOBUGLIO AF, LOECHEL F et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. (1995) 2(1)59–65.
   Google Scholar
• SCHREURS MWJ, DE BOER AJ, FIGDOR C, ADEMA GJ:Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. (1998) 58:2509–2514.
   PubMed Web of Science ®Google Scholar
• IRVINE KR, RAO JB, ROSENBERG SA, RESTIFO NP:Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol 156(1) 238–245.
   Google Scholar
• CONDON C, WATKINS SC, CELLUZZI CM, THOMPSON K, FALO LD et al: DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. (1996) 2(101122–1128.
   Google Scholar
• ZHAI Y, YANG JC, SPIESS P et al.: Cloning and characteri-zation of the genes encoding the murine homologues of the human melanoma antigens MART! and gp100.I Immunother. (1997) 20(0:15–25.
   PubMedGoogle Scholar
• SHIBAHARA S, TOMITA Y, SAKAKURA T et al.: Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res. (1986) 14(6):2413–2427.
   PubMed Web of Science ®Google Scholar
• NAFTZGER C, TAKECHI Y, KOHDA H et al.: Immuneresponse to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoim-munity. Proc. Natl. Acad. Sci. USA (1996) 93 (25):14809–14814.
   PubMed Web of Science ®Google Scholar
• JACKSON IJ, CHAMBERS DM, TSUKAMOTO K et al.: Asecond tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO J. (1992) 11(2):527–535.
   PubMed Web of Science ®Google Scholar
• NAWRATH M, PAVLOVIC J, DUMMET R et al. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pme117. Leukemia (1999) 13 (Suppl 1) S48–S51
   PubMedGoogle Scholar
• TUTING T, GAMBOTTO A, DELEO A et al.: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. (1999) 6(1)73–80.
   Google Scholar
• WEBER LW, BROWNE WB, WOLCHOK JD et al: Tumor immunity and autoimmunity induced by immuniza-tion with homologous DNA. J. Clin. Invest. (1998) 102 (6) :1258–1264.
   PubMed Web of Science ®Google Scholar
• AMICI A, VENANZI FM, CONCETTI A: Genetic immuniza-tion against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother. (1998) 47:183–190.
   PubMed Web of Science ®Google Scholar
• STEVENSON FK, ZHU D, KING CA et al.: Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. (1995) 145:211–228.
   PubMed Web of Science ®Google Scholar
• SYRENGELAS AD, CHEN TT, LEVY R: DNA immunization induces protective immunity against B-cell lymphoma. Nature Med. (1996) 2 (9):1038–1041.
   PubMed Web of Science ®Google Scholar
• HUANG AYC, GOLUMBEK P, AHMADZADEH M et al.: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264:961–965.
   PubMed Web of Science ®Google Scholar
• ••Identification of the role of bone marrow-derived antigenpresenting cells (APC) in the MHC class I-restricted immune response to tumours.
   Google Scholar
• CORR M, LEE DJ, CARSON DA, TIGHE H: Gene vaccina- tion with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. (1996) 184:1555–1560.
   PubMed Web of Science ®Google Scholar
• ••Description of the role of bone marrow-derived APCs inMHC class I-restricted presentation of antigens following im. pDNA gene delivery.
   Google Scholar
• SIGAL LI CROTTY S, ANDINO R, ROCK KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (1999) 398:77–80.
   PubMed Web of Science ®Google Scholar
• ALBERT ML, SAUTER B, BHARDWAJ N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392:86–89.
   PubMed Web of Science ®Google Scholar
• •Identification of a mechanism that may be involved in cross-priming of dendritic cells.
   Google Scholar
• STEWART MJ, PLAUTZ GE, DEL BUONO L et al.: Gene transfer in vivo with DNA-liposome complexes: Safety and acute toxicity in mice. Hum. Gene Ther. (1992) 3:267–275.
   Google Scholar
• NABEL EG, GORDON D, YANG Z-Y et al.: Gene transfer in vivo with DNA-liposome complexes: Lack of autoim-munity and gonadal localization. Hum. Gene Ther. (1992) 3:649–656.
   PubMed Web of Science ®Google Scholar
• SAN H, YANG Z-Y, POMPILI VJ et al.: Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. (1993) 4:781–788.
   PubMed Web of Science ®Google Scholar
• CANONICO AE, PLITMAN JD, CONARY JT, MEYRICK BO, BRIGHAM K: No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes. J. Appl. Physic)]. (1994) 77(1):415–419.
   PubMed Web of Science ®Google Scholar
• PARKER SE, VAHLSING HL, SERFILIPPI LM et al.: Cancer gene therapy using plasmid DNA: Safety evaluation in rodents and non-human primates. Hum. Gene Ther. (1995) 6:575–590.
   PubMed Web of Science ®Google Scholar
• NABEL GJ, NABEL EG, YANG Z-Y et al.: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. (1993) 90:11307–11311.
   PubMed Web of Science ®Google Scholar
• STOPECK AT, HERSH EM, AKOIRUAYE ET et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Gun. Oncol. (1996) 15:341–349.
   Web of Science ®Google Scholar
• LIU Y, LIGGIT D, ZHONG W et al: Cationic liposome-mediated intravenous gene delivery. J. Biol. Chem. (1995) 270(42):24864–24870.
   PubMed Web of Science ®Google Scholar
• MAHATO RI, KAWABATA K, TAKAUARA Y, HASHIDA M.:In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J. Drug Targeting (1995) 3:149–157.
   Google Scholar
• MAHATO RI, KAWABATA K, NOMURA K, TAKAUARA Y, HASHIDA M: Physicochemical and pharmacokinetic characterisitics of plasmid DNA/cationic liposome complexes. J. Pharm. Sci. (1995) 84 (1 0 :1267–1271.
   Google Scholar
• THIERRY AR, LUNARDI-ISKANDAR Y, BRYANT JL et al: Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc. Natl. Acad. Sci. USA (1995) 92:9742–9746.
   PubMed Web of Science ®Google Scholar
• LEW D, PARKER SE, LATIMER T et al: Cancer gene therapy using plasmid DNA: Pharmacokinetics study of DNA following injection in mice. Hum. Gene Ther. (1995) 6:553–564.
   PubMed Web of Science ®Google Scholar
• PARKER SE, BORELLINI F, WENK ML et al.: Plasmid DNA malaria vaccine: Tissue distribution and safety studies in mice and rabbits. Hum. Gene Ther. (1999) 10:741–758.
   PubMed Web of Science ®Google Scholar
• LE TP, COONAN KM, HEDSTROM RC et al: Safety, tolerability, and humoral immune response after intramuscular administration of a malaria vaccine to healthy adult volunteers. Vaccine. (In Press).
   Google Scholar
• WOLFF JA, LUDTKE JJ, ACSADI G WILLIAMS P, JANI A: Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. (1992) 1:363–369.
   PubMedGoogle Scholar
• HARTIKKA J, SAWDEY M, CORNEFORT-JENSEN F et al.: An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. (1996) 7:1205–1217.
   PubMed Web of Science ®Google Scholar
• MARTIN T, PARKER SE, HEDSTROM R et al: Plasmid DNAmalaria vaccine: The potential for genomic integra-tion after intramuscular injection. Hum. Gene Ther. (1999) 10:759–768.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL eta].: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:907–913.
   Google Scholar
• ROSENBERG SA, ZHAI Y, YANG JC et al.: Immunizing patients with metastatic melanoma using recombi-nant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Nad Cancer Inst. (1998) 90:1894–1900.
   PubMed Web of Science ®Google Scholar
• •Human clinical trial of adenoviral delivery of the melanoma tumour antigens, MART-1 or gp100.
   Google Scholar
• HORN NA, MEEK JA, BUDAHAZI G, MARQUET M: Cancer gene therapy: purification of DNA for human clinical trials. Hum. Gene Ther. (1995) 6:565–573.
   PubMed Web of Science ®Google Scholar
• MANTHORPE M, CORNEFERT-JENSEN F, HARTIKKA J: Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice. Hum. Gene Ther. (1993) 4:419–431.
   PubMed Web of Science ®Google Scholar
• CORMIER JN, HUAZI YM, ABATI A et al.: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer (1998) 75:517–524.
   PubMed Web of Science ®Google Scholar
• LEE K-H, PANELLI MC, KIM CJ et al.: Functional dissocia-tion between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. (1998) 161:4183–4194.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS, JAKOWATZ J, HAREL W et al.: Increased effectiveness of interferon alfa-2B following active specific immunotherapy for melanoma. J. Gin. Oncol (1994) 12:402–411.
   Web of Science ®Google Scholar
• FLEISCHMANN CM, STANTON GJ, FLEISCHMANN WR: Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. (1996) 16:805–812.
   PubMed Web of Science ®Google Scholar
• NISTICO P, TECCE R, GIACOMINI P et al: Effect ofrecombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res. (1990) 50:7422–7429.
   PubMed Web of Science ®Google Scholar